Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Merck
Mallinckrodt
AstraZeneca
McKesson
Baxter
Express Scripts

Last Updated: November 22, 2019

DrugPatentWatch Database Preview

Details for Patent: 5,753,677

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 5,753,677
Title: Benzoheterocyclic compounds
Abstract:Novel benzoheterocyclic compounds of the formula: ##STR1## which have excellent vasopressin antagonistic activities and are useful as vasodilator, hypotensive agent, water diuretics, platelet agglutination inhibitor, and a vasopressin antagonistic composition containing the compound as the active ingredient.
Inventor(s): Ogawa; Hidenori (Tokushima-ken, JP), Miyamoto; Hisashi (Kyoto-fu, JP), Kondo; Kazumi (Tokushima-ken, JP), Yamashita; Hiroshi (Tokushima-ken, JP), Nakaya; Kenji (Tokushima-ken, JP), Komatsu; Hajime (Tokushima-ken, JP), Tanaka; Michinori (Tokushima-ken, JP), Kora; Shinya (Nagasaki-ken, JP), Tominaga; Michiaki (Tokushima-ken, JP), Yabuuchi; Yoichi (Tokushima-ken, JP)
Assignee: Otsuka Pharmaceutical Co., Ltd. (Tokyo, JP)
Application Number:08/474,544
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 5,753,677
Patent Claim Types:
see list of patent claims
Use; Compound;

Drugs Protected by US Patent 5,753,677

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Otsuka Pharm Co Ltd JYNARQUE tolvaptan TABLET;ORAL 204441-001 Apr 23, 2018 RX Yes No   Start Trial   Start Trial TREATMENT OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE   Start Trial
Otsuka Pharm Co Ltd JYNARQUE tolvaptan TABLET;ORAL 204441-002 Apr 23, 2018 RX Yes No   Start Trial   Start Trial TREATMENT OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE   Start Trial
Otsuka Pharm Co Ltd JYNARQUE tolvaptan TABLET;ORAL 204441-003 Apr 23, 2018 RX Yes Yes   Start Trial   Start Trial TREATMENT OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE   Start Trial
Otsuka Pharm Co Ltd JYNARQUE tolvaptan TABLET;ORAL 204441-004 Apr 23, 2018 RX Yes No   Start Trial   Start Trial TREATMENT OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE   Start Trial
Otsuka Pharm Co Ltd JYNARQUE tolvaptan TABLET;ORAL 204441-005 Apr 23, 2018 RX Yes No   Start Trial   Start Trial TREATMENT OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim
Colorcon
Medtronic
Harvard Business School
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.